This article is more than 5 years old. Information may no longer be current.

NovoPen Echo device cleared by FDA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has given clearance to a new insulin device which is expected to hit US markets in early 2014, according to a press release. It has already been marketed in Europe, Canada and Israel.

The NovoPen Echo (NovoNordisk) is said to be the first and only diabetes pen device in the US with half-unit dosing and a memory function that has the capability to record dosages and time passed since the last injection, according to the press release.

NovoPen Echo will be available to patients who use insulin aspart (NovoLog) PenFill cartridges.

According to the press release, the device’s half-unit dosing versatility will give patients accurate adjustments. Customizable skins will also be available for the devices’ youngest users.

For more information:

NovoNordisk’s NovoPen Echo.